<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2016-11-15" updated="2019-12-02">
  <drugbank-id primary="true">DB13144</drugbank-id>
  <name>Lenograstim</name>
  <description>Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.</description>
  <cas-number>135968-09-1</cas-number>
  <unii>6WS4C399GB</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18828</ref-id>
        <pubmed-id>10776839</pubmed-id>
        <citation>Dunn CJ, Goa KL: Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs. 2000 Mar;59(3):681-717.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L529</ref-id>
        <title>Medsafe</title>
        <url>http://www.medsafe.govt.nz/profs/Datasheet/g/Granocyteinj.htm</url>
      </link>
      <link>
        <ref-id>L530</ref-id>
        <title>Wikipedia</title>
        <url>https://en.wikipedia.org/wiki/Lenograstim</url>
      </link>
      <link>
        <ref-id>L531</ref-id>
        <title>ChemIDPlus</title>
        <url>https://chem.nlm.nih.gov/chemidplus/rn/135968-09-1</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. &#13;
Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy.&#13;
Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim  is also indicated to accelerate the engraftment of these cells after their reinfusion.&#13;
&#13;
GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).</indication>
  <pharmacodynamics>Lenograstim has been confirmed as a valuable adjunct to minimise the haematological toxicity of myelosuppressive chemotherapy in patients with malignant disease. The drug also enhances neutrophil recovery in patients undergoing stem cell rescue, and assists peripheral blood progenitor cells mobilisation.</pharmacodynamics>
  <mechanism-of-action>Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor. Lenograstim accelerates neutrophil recovery significantly after chemotherapy, with beneficial effects on clinical end-points such as incidence of laboratory-confirmed infection and length of hospital stay. Chemotherapy dose intensity has also been increased in patients receiving lenograstim, notably those with breast or small cell lung cancer, although improvements in tumour response and survival have not been demonstrated. Lenograstim also assists neutrophil recovery in patients undergoing bone marrow transplantation, and stimulates the production of peripheral blood stem cells (PBSCs) for autologous transfusion after aggressive chemotherapy.</mechanism-of-action>
  <toxicity>Species observed : Human (Man)&#13;
Test type: TDLo ( Lowest Published Toxic Dose)&#13;
Route of exposure: Subcutaneous&#13;
Dose/Duration: 21428mg/kg/15&#13;
Toxic Effect: &#13;
      Skin and appendages: Dermatitis, allergic ( after systemic exposure )&#13;
&#13;
Species observed : Rodent - Rat&#13;
Test type: LD50&#13;
Route of exposure: Oral&#13;
Dose/Duration: &gt;5mg/kg&#13;
Toxic Effect: Details of toxic effects not reported other than lethal dose value&#13;
&#13;
Species observed : Rodent -  Rat&#13;
Test type: LD50&#13;
Route of exposure: Subcutaneous&#13;
Dose/Duration:  &gt;5mg/kg&#13;
Toxic Effect: Details of toxic effects not reported other than lethal dose value&#13;
&#13;
Species observed : Rodent -  Rat&#13;
Test type: LD50&#13;
Route of exposure:  Intravenous&#13;
Dose/Duration:  &gt;5mg/kg&#13;
Toxic Effect: Details of toxic effects not reported other than lethal dose value&#13;
&#13;
Species observed : Mammal - Dog&#13;
Test type: LD50&#13;
Route of exposure: Intravenous&#13;
Dose/Duration:  &gt;5mg/kg&#13;
Toxic Effect: Details of toxic effects not reported other than lethal dose value&#13;
&#13;
Species observed : Mammal - Dog&#13;
Test type: LD50&#13;
Route of exposure: Subcutaneous&#13;
Dose/Duration:  &gt;5mg/kg&#13;
Toxic Effect: Details of toxic effects not reported other than lethal dose value</toxicity>
  <metabolism>Lenograstim is metabolised to peptides.</metabolism>
  <absorption>During repeated dosing (iv and sc routes), peak serum concentrations (at the end of iv infusion or after sc injection) are proportional to the injected dose. Repeated dosing with lenograstim  by the two injection routes results in no evidence of drug accumulation.</absorption>
  <half-life>The pharmacokinetic profile of lenograstim  is similar in healthy volunteers and cancer patients with elimination half-life (t½β) values of 2.3 - 3.3 hrs (volunteers); 2.8-7.5 hrs (cancer patients) following sc administration, and 0.8 - 2.1 hrs (volunteers); 1.1 - 4.0 hrs (cancer patients) following iv administration.</half-life>
  <protein-binding/>
  <route-of-elimination>Lenograstim is poorly excreted in urine as intact compound (less than 1% of the dose).</route-of-elimination>
  <volume-of-distribution>Apparent distribution volume (Vd area) is approximately 52 ± 5 mL/kg body weight.&#13;
</volume-of-distribution>
  <clearance>Plasma clearance of lenograstim increased 3-fold (from 50 up to 150 mL/min) during repeated sc dosing.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">G-CSF (CHO cell derived)</synonym>
    <synonym language="english" coder="">Glycosylated recombinant G-CSF</synonym>
    <synonym language="english" coder="">Glycosylated recombinant granulocyte colony stimulating factor</synonym>
    <synonym language="english" coder="">Granulocyte colony stimulating factor 3 (CHO cell derived)</synonym>
    <synonym language="english" coder="">Granulocyte colony-stimulating factor lenograstim</synonym>
    <synonym language="english" coder="inn/ban/usan">Lenograstim</synonym>
    <synonym language="english" coder="">Lenograstim (genetical recombination)</synonym>
    <synonym language="english" coder="">Lenograstim rDNA</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Granocyte</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Neutrogin</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Colony-Stimulating Factors</category>
      <mesh-id>D003115</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycoproteins</category>
      <mesh-id>D006023</mesh-id>
    </category>
    <category>
      <category>Granulocyte Colony-Stimulating Factors</category>
      <mesh-id>D016179</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hematopoietic Cell Growth Factors</category>
      <mesh-id>D016298</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes>
    <atc-code code="L03AA10">
      <level code="L03AA">Colony stimulating factors</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of pulmonary toxicity can be increased when Lenograstim is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The risk or severity of neutropenia can be increased when Lenograstim is combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05168</drugbank-id>
      <name>Vintafolide</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vintafolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vinflunine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vincamine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911430</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Lenograstim</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000793</id>
      <name>Granulocyte colony-stimulating factor receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L532</ref-id>
            <title>UniProt</title>
            <url>http://www.uniprot.org/uniprot/Q99062</url>
          </link>
          <link>
            <ref-id>L533</ref-id>
            <title>KEGG</title>
            <url>http://www.kegg.jp/dbget-bin/www_bget?hsa:1441</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q99062" source="Swiss-Prot">
        <name>Granulocyte colony-stimulating factor receptor</name>
        <general-function>Receptor activity</general-function>
        <specific-function>Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface.</specific-function>
        <gene-name>CSF3R</gene-name>
        <locus>1p35-p34.3</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions>628-650</transmembrane-regions>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi>6.14</theoretical-pi>
        <molecular-weight>92155.615</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2439</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CSF3R</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X55721</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31697</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q99062</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CSF3R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>G-CSF receptor</synonym>
          <synonym>GCSFR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001582|Granulocyte colony-stimulating factor receptor
MARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQ
ILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAG
YPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPK
DGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPE
AAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPA
TAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVP
LEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPT
PVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRME
QNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGK
TWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHL
MAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP
SVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGL
PTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGL
TPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010560|Granulocyte colony-stimulating factor receptor (CSF3R)
ATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCC
GGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGAT
CCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAG
ATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGAT
GGGACCCAGGAATCTATCATCACCCTGCCCCACCTCAACCACACTCAGGCCTTTCTCTCC
TGCTGCCTGAACTGGGGCAACAGCCTGCAGATCCTGGACCAGGTTGAGCTGCGCGCAGGC
TACCCTCCAGCCATACCCCACAACCTCTCCTGCCTCATGAACCTCACAACCAGCAGCCTC
ATCTGCCAGTGGGAGCCAGGACCTGAGACCCACCTACCCACCAGCTTCACTCTGAAGAGT
TTCAAGAGCCGGGGCAACTGTCAGACCCAAGGGGACTCCATCCTGGACTGCGTGCCCAAG
GACGGGCAGAGCCACTGCTGCATCCCACGCAAACACCTGCTGTTGTACCAGAATATGGGC
ATCTGGGTGCAGGCAGAGAATGCGCTGGGGACCAGCATGTCCCCACAACTGTGTCTTGAT
CCCATGGATGTTGTGAAACTGGAGCCCCCCATGCTGCGGACCATGGACCCCAGCCCTGAA
GCGGCCCCTCCCCAGGCAGGCTGCCTACAGCTGTGCTGGGAGCCATGGCAGCCAGGCCTG
CACATAAATCAGAAGTGTGAGCTGCGCCACAAGCCGCAGCGTGGAGAAGCCAGCTGGGCA
CTGGTGGGCCCCCTCCCCTTGGAGGCCCTTCAGTATGAGCTCTGCGGGCTCCTCCCAGCC
ACGGCCTACACCCTGCAGATACGCTGCATCCGCTGGCCCCTGCCTGGCCACTGGAGCGAC
TGGAGCCCCAGCCTGGAGCTGAGAACTACCGAACGGGCCCCCACTGTCAGACTGGACACA
TGGTGGCGGCAGAGGCAGCTGGACCCCAGGACAGTGCAGCTGTTCTGGAAGCCAGTGCCC
CTGGAGGAAGACAGCGGACGGATCCAAGGTTATGTGGTTTCTTGGAGACCCTCAGGCCAG
GCTGGGGCCATCCTGCCCCTCTGCAACACCACAGAGCTCAGCTGCACCTTCCACCTGCCT
TCAGAAGCCCAGGAGGTGGCCCTTGTGGCCTATAACTCAGCCGGGACCTCTCGTCCCACT
CCGGTGGTCTTCTCAGAAAGCAGAGGCCCAGCTCTGACCAGACTCCATGCCATGGCCCGA
GACCCTCACAGCCTCTGGGTAGGCTGGGAGCCCCCCAATCCATGGCCTCAGGGCTATGTG
ATTGAGTGGGGCCTGGGCCCCCCCAGCGCGAGCAATAGCAACAAGACCTGGAGGATGGAA
CAGAATGGGAGAGCCACGGGGTTTCTGCTGAAGGAGAACATCAGGCCCTTTCAGCTCTAT
GAGATCATCGTGACTCCCTTGTACCAGGACACCATGGGACCCTCCCAGCATGTCTATGCC
TACTCTCAAGAAATGGCTCCCTCCCATGCCCCAGAGCTGCATCTAAAGCACATTGGCAAG
ACCTGGGCACAGCTGGAGTGGGTGCCTGAGCCCCCTGAGCTGGGGAAGAGCCCCCTTACC
CACTACACCATCTTCTGGACCAACGCTCAGAACCAGTCCTTCTCCGCCATCCTGAATGCC
TCCTCCCGTGGCTTTGTCCTCCATGGCCTGGAGCCCGCCAGTCTGTATCACATCCACCTC
ATGGCTGCCAGCCAGGCTGGGGCCACCAACAGTACAGTCCTCACCCTGATGACCTTGACC
CCAGAGGGGTCGGAGCTACACATCATCCTGGGCCTGTTCGGCCTCCTGCTGTTGCTCACC
TGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAGGAAGAATCCCCTCTGGCCA
AGTGTCCCAGACCCAGCTCACAGCAGCCTGGGCTCCTGGGTGCCCACAATCATGGAGGAG
GATGCCTTCCAGCTGCCCGGCCTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAG
GAGGATGAAAAGAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTC
CCCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCC
CAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCAGCTGCTGGGCAGCCCCACA
AGCCCAGGGCCAGGGCACTATCTCCGCTGTGACTCCACTCAGCCCCTCTTGGCGGGCCTC
ACCCCCAGCCCCAAGTCCTATGAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTG
GTAACCCCAGCCCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCC
CTCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00041</identifier>
            <name>fn3</name>
          </pfam>
          <pfam>
            <identifier>PF06328</identifier>
            <name>Lep_receptor_Ig</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cytokine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>amelogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of myeloid cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>